Scholars Central

Research articlePublished 30 Jun 2022

Therapeutic Efficacy and Long-term Treatment Outcome of DPP-4 Inhibitors as an add-on Therapy with Metformin and Sulfonylureas in T2DM Patients at GP Clinics of Southern Odisha

Authors: Premakanta Mohanty, Chinmaya Debasis Panda, Pradyut Kumar Pradhan

Journal of Research in Medical and Dental Science

Volume 10 · Issue 6 · Pages 117–123

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Introduction: Diabetes is a global health concern with T2DM being the most common type. Medical science has hardly been successful in managing this condition and its associated co-morbidities and complications. Most interestingly although it’s a condition primarily referred to super specialists, it has to be primarily managed by general practioners in primary healthcare setups. GPs face many problems in diabetes management, one of which is non-availability of a universal treatment guideline applicable to all patients. Hence to evaluate individual newer drugs like DPP-4 inhibitors for their efficacy, safety and long-term treatment outcome, this study was conducted. Aim and objective: To provide evidence about the therapeutic efficacy and long-term treatment outcomes in T2DM patients treated with DPP-4 inhibitors as an add-on therapy with metformin and sulfonylureas. Methodology: A sample of 153 T2DM patients with disease duration of around 5 years was selected who were being treated in GP clinics of southern Odisha. Among them around 74 patients were isolated who were taking either a combination of metformin and sulfonylureas (Group-A) or metformin, sulfonylureas and DPP-4 inhibitors (Group-B). Patient past data like their demography, blood glucose level, HBA1C level etc. were collected from their personal treatment files using a structured case record form and was statically evaluated to extract the efficacy with complication and co-morbidity outcomes in patients with and without DPP-4 inhibitors in their treatment regimen. Discussion and conclusion: In our study it was found that DPP-4 Inhibitors significantly improved glycemic outcome (OR, 2.862; 95% CI, 1.349-6.069) as compared to the control group (OR, 0.845; 95% CI, 0.299-2.385). Treatment group had shown relatively better blood pressure control (OR, 0.997; 95% CI, 0.487-2.043) than control group (OR, 0.114; 95% CI, 0.025-0.529). No statistically significant relationship could be established between DPP-4 Inhibitors and any of the chronic complications of T2DM. Further studies are needed to evaluate and establish the findings of our study.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Research in Medical and Dental Science.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Research in Medical and Dental Science
  • SubjectDentistry & Oral Health
  • BylineArticles whose byline prints “Premakanta Mohanty”
  • BylineArticles whose byline prints “Chinmaya Debasis Panda”
  • BylineArticles whose byline prints “Pradyut Kumar Pradhan”